榮盛發展(002146.SZ):完成境外發行3億美元高級無抵押定息債券
格隆匯 1 月 20日丨榮盛發展(002146.SZ)公佈,2021年1月20日,公司境外間接全資子公司RongXinDa Development (BVI) Limited完成境外發行3億美元的高級無抵押定息債券,債券期限為364天,票面利率為8.95%。此次發行的債券由公司提供無條件及不可撤銷的跨境連帶責任保證擔保。本次債券發行依據美國證券法S條例向專業投資人發售,並在新加坡交易所上市,上市日期為2021年1月20日,3億美元高級無抵押定息債券代碼為XS2280638607。
此次美元債券的發行有利於改善公司債務結構、拓寬融資渠道,滿足資金需求,提升公司境外市場信用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.